Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease

NCT00972660 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease

Interventions

BIOLOGICAL: Mesenchymal stem cell (MSC)
DRUG: Prednisone and cyclosporine or primary therapies

Sponsor

Guangdong Provincial People's Hospital

Collaborators

[object Object]